Ebglyss TM
You should seek medical advice in relation to medicines and use only as directed by a healthcare professional. Always read the label. If symptoms persist see your healthcare professional.
Active ingredients: etrasimod
Pack: Ebglyss 250 mg/2 mL injection, 2 mL pen device
Brand name
(ARTG)
: EBGLYSS lebrikizumab 250 mg/2 mL solution for injection autoinjector (pre-filled pen)Download the Consumer Medicine Information Leaflet
Download consumer medicine information leaflet (pdf) from the Therapeutic Goods Administration (TGA) website
What this medicine is used for
(ARTG)
EBGLYSS is indicated for the treatment of adult and adolescent patients (12 years of age and older) with moderate-to-severe atopic dermatitis (AD) who are candidates for systemic therapy.
How to use this medicine
(ARTG)
This medicine contains one component only.
Component :
- Injection, solution
- Subcutaneous
- Clear to opalescent, colourless to slightly yellow to slightly brown solution, free of visible particles.
Storage conditions
(ARTG)
- Store at 2 to 8 degrees Celsius
- Protect from Light
- Do not Freeze
- Refrigerate
- Do not Shake
- Shelf lifetime is 18 Months.
Do I need a prescription ?
(ARTG)
These medicine packs are available from a pharmacist and requires a prescription. It is
- 1 pack
- 1 (Starter Pack) pack
Pregnant or planning a pregnancy ?
(AHT)
For the active ingredient etrasimod
You should seek advice from your doctor or pharmacist about taking this medicine. They can help you balance the risks and the benefits of this medicine during pregnancy.
Reporting side effects
This medicine is under additional monitoring as it is new or being used in a different way. You can help identify new safety information by reporting any side effects you may get.
- You can report side effects to your doctor, or directly at www.tga.gov.au/reporting-problems.
- For more information on the Black Triangle Scheme and how to report side effects, see www.tga.gov.au/black-triangle-scheme
